Immune profiles in Bone marrow to predict induce therapy response for multiple myeloma patients

Purpose: To find bone marrow immune detection index which related to MM patients therapy. Method: We analyzed ninety-three newly diagnosed MM patients retrospectively and their the stage of prognosis, the clinical and induced-therapy response datasets. Result: In our study, Eight-color flow cytometry, a method commonly used to detect MM cell loads, was used to analyze seven bone marrow immune cell groups (B, NK, T, naive B, immature B, memory B, and plasmablast like cells). The percentage of B cells significantly decreased in stage III, compared with stage I patients, (P = 0.047, P = 0.038) according to the ISS and R-ISS. In the clinical characteristics, naive B cell numbers increased in the Hb(g/L)≥100 group, when compared with the Hb(g/L)< 100 group (P = 0.028). The immature B (P = 0.017), plasmablast like cell subgroups(P = 0.037) increased in MM patients, who achieved a very good partial response(VGPR), after four cycles of the new drug-based induced therapy. The ROC results indicated the combination of the seven immune subgroups had predictive values (AUC = 0.840; P < 0.0001). Conclusion: comprehensively analyze seven bone marrow immune cell subgroups can be a useful approach for predicting the induce therapy response in MM patients.